Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir.

ABSTRACT:

Background

There is scant data on young children receiving protease inhibitor-based therapy in real-life resource-limited settings and on the optimal timing of therapy among children who survive infancy. Our aim was to evaluate outcomes at the Hospital del Niño, Panama, where children have been routinely treated with lopinavir/ritonavir (LPV/r)-based therapy since 2002.

Methods

Retrospective cohort analysis of all HIV-infected children enrolled in care between January 1, 1991, and June 1, 2011. Kaplan-Meier method and Cox proportional hazards regression were used to evaluate death, virologic suppression and virologic rebound.

Results

Of 399 children contributing 1944 person-years of follow-up, 254 (63.7%) were treated with LPV/r and 94 (23.6%) were never treated with

SUBMITTER: Estripeaut D 

PROVIDER: S-EPMC3883902 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature